STUDY SHOWS INCREASES IN NET INCIDENCE, PREVALENCE, AND SURVIVAL

Why this may be good news

A pivotal study of close to 65,000 patients over almost forty years shows significant changes in the incidence, prevalence, and overall survival of NETs. What are the implications of these major findings? Learn where and how we are making headway. (MORE)

A ONE-OF-A-KIND SYMPOSIUM

Reflection of the NETRF Director of Research

The Neuroendocrine Tumor Research Foundation (NETRF) recently held its Annual Research Symposium at the beautiful Samberg Conference Center - MIT, in Cambridge, MA, overlooking the Charles River and the city of Boston. (MORE)

Advocacy

LET’S COVER PRE-EXISTING CONDITIONS

by Ron Hollander, Executive Director, NETRF

NETRF’s Executive Director shares his thoughts on the American Health Care Act (ACHA) proposed to replace the Affordable Care Act or “Obamacare.” How could this change potentially affect cancer patients? (MORE)

NATIONAL CANCER SURVIVORS DAY

Sunday, June 4, 2017

NETRF recognizes National Cancer Survivors Day as a celebration for those who have survived NETs, an inspiration for those who have been recently diagnosed, and as a chance to support families, caregivers, and care providers.

Please join in the conversation #NCSD2017 #NETthriver on our Facebook and Twitter pages.

Research

NET CLINICAL TRIAL LAUNCHES

Clinical researchers at MD Anderson Cancer Center are studying a new combination of therapies in neuroendocrine tumors (NETs). Researchers hope using an immunotherapy in combination with an anti-VEGF therapy will slow progression of the disease and extend survival. (MORE)

Education

2017 ANNUAL LOS ANGELES NEUROENDOCRINE TUMOR PATIENT EDUCATION CONFERENCE

Leaders in the field come together to offer the latest information in a daylong event on Saturday, June 24, to discuss NET treatment, research, and survivorship. You will learn about emerging treatment approaches like PRRT and immunotherapy, plus advanced imaging and surgical techniques. Speakers will also share hands-on tips for improved nutrition and wellness. (MORE)

Awards and Recognition

Anil K. Rustgi, MD, AGAF, a member of the NETRF Board of Scientific Advisors has been given the esteemed 2017 Julius Friedenwald Award by the American Gastroenterological Association. Dr. Rustgi is T. Grier Miller Professor of Medicine and Genetics, Chief of the Gastroenterology Division and Director of the NIH/NIDDK P30 Center for Molecular Studies in Digestive and Liver Diseases at the University of Pennsylvania, Philadelphia.

Guillermina (Gigi) Lozano, PhD, NETRF Petersen Investigator, has been named a member of the National Academy of Sciences in recognition of her distinguished and continuing achievements in original research. Dr. Lozano is Professor and Chair, Department of Genetics, The University of Texas M.D. Anderson Cancer Center, Houston.

Hans Clevers, MD, PhD, a 2017 NETRF Accelerator Award grantee, has been named one of fifteen finalists for the European Inventor Award 2017 by the European Patent Office (EPO). This "favorite inventor" award recognizes contributions to advancing technology and generating economic value and employment in Europe and beyond. Vote here for Hans Clevers.

We are pleased to announce that this eUpdate
is sponsored by Novartis Pharmaceutical Corporation.

DONATE

The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.

Manage your preferences | Opt out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.

20 Park Plaza, Suite 478
Boston, MA | 02116 US

This email was sent to .
To continue receiving our emails, add us to your address book.

Subscribe to our email list.